Verastem Inc
VSTM
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
75% downsideOvervalued by 75% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $284.19 Million |
|---|---|
| Enterprise Value | $194.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.02 |
| Beta | 0.27 |
| Outstanding Shares | 98,292,000 |
Return
| Return on Equity | -237.18% |
|---|---|
| Return on Assets | -85.14% |
| Return on Invested Capital | -94.93% |
Valuation & Multiples
| P/E Ratio | -2.08 |
|---|---|
| PEG | 6.98 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.92 |
| Enterprise Value to EBIT | -1.27 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.39 |
| Debt to Equity | 0.93 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0453▼ 24.48% |
|---|---|
| Total Calls | 708,000▲ 53.28% |
| Total Puts | 32,100▼ 76.04% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.58%▼ 6.99% |
|---|---|
| Total Invested | $431.47M▼ 26.94% |
| Investors Holding | 162▲ 12.00% |
ESG Score
No data
About Verastem Inc
CEO: Brian Stuglik Relevant Senate Committees
The Finance Committee controls Medicare and Medicaid reimbursement policy and drug pricing legislation, directly impacting Verastem's revenue potential and commercial viability.
This committee determines the annual funding levels for the FDA and NIH, which dictates the resources available for drug reviews and basic science research.
This committee directly oversees the FDA and NIH, regulating drug approvals, clinical trial standards, and federal research funding critical to Verastem.
This committee oversees intellectual property and patent laws, which are the primary assets of pharmaceutical companies; it also oversees antitrust review of drug company mergers.